Serotype distribution and penicillin-non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines

References

• World Health Organization. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Weekly Epidemiol Rec. 2007;82(12):93–104.
   PubMedGoogle Scholar
• Linares J, Ardanuy C, Pallares R, et al. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect. 2010;16:402–410.
   PubMed Web of Science ®Google Scholar
• Mokaddas EM, Wilson S, Sanyal SC. Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait. J Chemother. 2001;13(2):154–160.
   PubMed Web of Science ®Google Scholar
• Mokaddas EM, Rotimi VO, Albert MJ. Increasing prevalence of antimicrobial resistance in Streptococcus pneumoniae in Kuwait: implications for therapy. Microb Drug Resist. 2007;13(4):227–233.
   PubMed Web of Science ®Google Scholar
• Mokaddas EM, Rotimi VO, Albert MJ. Implications of Streptococcus pneumoniae penicillin resistance and serotype distribution in Kuwait for disease treatment and prevention. Clin Vaccine Immunol. 2008;15(2):203–207.
   PubMed Web of Science ®Google Scholar
• Lee LH, Gu -X-X, Nahm MH. Towards new broader spectrum pneumococcal vaccines: the future of pneumococcal disease prevention. Vaccines. 2014;2(1):112–128.
   PubMedGoogle Scholar
• Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implication for conjugate vaccine formulation and use, Part 1. Clin Infect Dis. 2000;30(1):100–121.
   PubMed Web of Science ®Google Scholar
• Shibl AM, Memish ZA, Al-Kattan KM. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA). Vaccine. 2012;30(suppl 6):G32–G36.
   PubMed Web of Science ®Google Scholar
• Sorensen UB. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol. 1993;31(8):2097–2100.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement; M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
   Google Scholar
• Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999–2011. Emerg Infect Dis. 2013;19(7):1074–1083.
   PubMed Web of Science ®Google Scholar
• Caierão J, Hawkins P, Sant’anna FH, et al. Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil. PLoS ONE. 2014;9(10):e111129.
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244–256.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro Surveill. 2008;13(35):pii:18962.
   PubMedGoogle Scholar
• Van der Linden M, Weiß S, Falkenhorst G, et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine. 2012;30(40):5880–5885.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varonb E, Georgesa S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine. 2015;33(2):359–366.
   PubMed Web of Science ®Google Scholar
• Richter SS, Diekeema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484–6489.
   PubMed Web of Science ®Google Scholar
• De Miguel-Martinez I, Ramos-Macias A, Borkoski Bareiro S. Efficacy of heptavalent pneumococcal conjugate vaccine in children with cochlear implant. Acta Otorrinolaryngol Esp. 2008;59(1):2–5.
   PubMedGoogle Scholar
• Rivera-Olivero IA, delNogal B, Fuentes M, et al. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases. Vaccine. 2014;32(31):4006–4011.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–1746.
   PubMed Web of Science ®Google Scholar
• Wei S-H, Chiang C-S, Chiu C-H, et al. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2015;34(3):e71–e77.
   PubMed Web of Science ®Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, et al. Systemic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J. 2014;33(Suppl 2):S140–S151.
   PubMed Web of Science ®Google Scholar
• Taylor S, Marchisio P, Vergison A, et al. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis. 2012;54(12):1765–1773.
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31(3):297–301.
   PubMed Web of Science ®Google Scholar
• Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol. 1995;33(10):2759–2762.
   PubMed Web of Science ®Google Scholar
• Dias R, CaniÃa M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol Med Microbiol. 2007;51(1):35–42.
   PubMedGoogle Scholar
• Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax. 1998;53(3):159–162.
   PubMed Web of Science ®Google Scholar
• Shibl AM. Distribution of serotypes and antibiotic resistance of invasive pneumococcal disease isolates among children aged 5 years and under in Saudi Arabia (2000–2004). Clin Microbiol Infect. 2008;14(9):876–879.
   PubMed Web of Science ®Google Scholar
• Sleeman KL, Griffiths D, Shackley F, et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis. 2006;194(5):682–688.
   PubMed Web of Science ®Google Scholar
• Sa-Leao R, Pinto F, Aguiar S, et al. Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behaviour of clones expressing the same serotype. J Clin Microbiol. 2011;49(4):1369–1375.
   PubMed Web of Science ®Google Scholar
• Shouval DS, Greenberg D, Givon-Lavi N, et al. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J. 2006;25(7):602–607.
   PubMed Web of Science ®Google Scholar
• Morais L, Da Gloria Carvalho M, Roca A, et al. Sequential multiplex PCR for identifying pneumococcal capsular serotypes from south-Saharan African clinical isolates. J Med Microbiol. 2007;56:1181–1184.
   PubMed Web of Science ®Google Scholar
• Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines. 2014;2(6):155–158.
   PubMedGoogle Scholar
• Tasslimi A, Sison EJ, Story E, et al. Disappearance of vaccine type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates. Clin Vaccine Immunol. 2009;16(8):1256–1259.
   PubMed Web of Science ®Google Scholar
• Van der Linden M, Falkenhorst G, Perniciaro S, et al. Effects of infant pneumococcal vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS ONE. 2015;10(7):e0131494.
   PubMed Web of Science ®Google Scholar
• Thoon KC, Chong CY, Tee NWS. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. Int J Infect Dis. 2012;16:e209–e215.
   PubMed Web of Science ®Google Scholar
• Lacapa R, Bliss SJ, Larzelere-Hinton F, et al. Changing epidemiology of invasive pneumococcal disease among White Moutain Apache persons in the era of pneumococcal conjugate vaccine. Clin Infect Dis. 2008;47(4):476–484.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J Immunol Res. 2015;2015:6. Article ID 591580.
   Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–309.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452–3459.
   PubMed Web of Science ®Google Scholar
• Levy C, Varon E, Picard C, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. Pediatr Infect Dis J. 2014;33(12):1216–1221.
   PubMed Web of Science ®Google Scholar
• Demczuk WHB, Martin I, Griffith A, et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012. Canadian J Microbiol. 2013;58(8):1008–1017.
   Web of Science ®Google Scholar
• Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8(12):785–795.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Slack MPE, Andrews NJ, et al. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England Wales. Emerg Infect Dis. 2013;19(1):61–68.
   PubMed Web of Science ®Google Scholar
• Myint TTH, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–151.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998–2005. MMWR Morb Mortal Wkly Rep. 2008;57(6):144–148.
   PubMedGoogle Scholar
• Steens A, Begsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–6238.
   Google Scholar
• Rodenburg GD, De Greeff SC, Jansen AG, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis. 2010;16(5):816–823.
   PubMed Web of Science ®Google Scholar
• Guevara M, Barricarte A, Gil-Setas A, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009;15(11):1013–1019.
   PubMed Web of Science ®Google Scholar
• Galanis I, Lindstrand A, Darenberg J, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Resp J. 2016;47(4):1208–1218.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hajjeh R, Al-Mazrou A, et al. The epidemiology of pneumococcal and meningococcal, and Haemophilus in the Middle East and North Africa (MENA) region-current status and needs. Vaccine. 2007;25(11):1935–1944.
   PubMed Web of Science ®Google Scholar
• Al-Yaqoubi EKM. Serotype prevalence and penicillin susceptibility of Streptococcus pneumoniae in Oman. Oman Med J. 2011;26:43–47.
   PubMedGoogle Scholar
• Khoshdel A, Rastabi RI, Doosti A, et al. Prevalence of heptavalent vaccine-related pneumococcal serotypes in nasopharyngeal carrier in children under five years old in Shahrekord, Iran by multiplex-PCR during 2010–2011. J Clin Diagn Res. 2014;8(11):PC01–PC04.
   PubMedGoogle Scholar
• Miyaji EN, Oliveira MLS, Carvalho E, et al. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70(18):3303–3326.
   PubMed Web of Science ®Google Scholar